$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
服用特罗凯耐药后怎么办?
2025-10-19 11:44:20
Check Details
服用易瑞沙出现胃肠道不适怎么办?
2025-10-19 11:44:20
Check Details
舒尼替尼治疗肺癌安全耐受
2025-10-19 11:44:20
Check Details
阿法替尼延长EGFR敏感突变肺癌患者无进展生存时间
2025-10-19 11:44:20
Check Details
阿法替尼治疗晚期肺鳞癌
2025-10-19 11:44:20
Check Details
舒尼替尼与化疗联合治疗NSCLC患者安全耐受
2025-10-19 11:44:20
Check Details
易瑞沙可用于晚期化疗失败的肺癌患者
2025-10-19 11:44:20
Check Details
特罗凯治疗肺鳞癌效果优于化疗
2025-10-19 11:44:20
Check Details
色瑞替尼治疗ALK阳性NSCLC疗效优于化疗
2025-10-19 11:44:20
Check Details
肺癌患者服用舒尼替尼常见的不良反应
2025-10-19 11:44:20
Check Details
克唑替尼使ROS1阳性NSCLC获益
2025-10-19 11:44:20
Check Details
奥希替尼治疗EGFR突变阳性的NSCLC有效率高达80%
2025-10-19 11:44:20
Check Details
1
2
...
9068
9069
9070
9071
9072
9073
9074
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
2
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
3
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
6
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
7
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
8
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
9
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
12
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission